WS #16755
BioNTech and Pfizer both reported Q3 earnings beats, with BioNTech raising its full-year revenue outlook and Pfizer increasing guidance. This performance reflects the sector's resilience and the successful execution of pipeline projects. The positive results provide a defensive anchor in the current volatile market, attracting capital to healthcare stocks as investors seek stability amid geopolitical and macroeconomic uncertainty.
Healthcare Earnings Resilience
BioNTech and Pfizer both reported Q3 earnings beats, with BioNTech raising its full-year revenue outlook and Pfizer increasing guidance. This performance reflects the sector's resilience and the successful execution of pipeline projects. The positive results provide a defensive anchor in the current volatile market, attracting capital to healthcare stocks as investors seek stability amid geopolitical and macroeconomic uncertainty.